Taysha Gene Therapies, Inc. Income Statement

Income Statement Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue -0.03M-1.43M2.50M15.45M8.33M
Gross Profit -0.03M-1.43M2.50M15.45M8.33M
Operating items
Research & Development 31.89M131.94M91.17M56.78M66.00M
Selling, General & Administrative 11.11M41.32M37.36M30.05M28.95M
Other Operating Expenses 36.42M1.06M4.84M
Operating Expenses 43.00M173.27M164.95M87.89M99.79M
Operating Income -43.00M-173.27M-162.45M-72.44M-91.46M
EBIT -43.00M-173.27M-162.45M-72.44M-91.46M
Non-operating items
Interest & Investment Income 0.05M0.17M0.25M3.57M6.94M
Other Non Operating Income -0.02M34.72M-0.11M
Non Operating Income -17.01M-1.26M-3.57M-39.13M2.16M
Net income details
EBT -42.98M-174.52M-166.00M-73.86M-84.62M
Profit After Tax -60.01M-174.52M-166.01M-111.57M-89.30M
Income from Continuing Operations -42.98M-174.52M-166.00M-73.86M-84.62M
Consolidated Net Income -42.98M-174.52M-166.00M-73.86M-84.62M
Income towards Parent Company -42.98M-174.52M-166.00M-73.86M-84.62M
Net Income towards Common Stockholders -60.01M-174.52M-166.01M-111.57M-89.30M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 37.76M38.47M62.44M186.96M205.00M
Shares Outstanding (Diluted Average) 43.95M116.12M250.13M
EBITDA -43.00M-173.27M-162.45M-72.44M-91.46M